These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Interferon-gamma enhances human eosinophil effector functions induced by granulocyte-macrophage colony-stimulating factor or interleukin-5. Yamaguchi T; Kimura H; Kurabayashi M; Kozawa K; Kato M Immunol Lett; 2008 Jun; 118(1):88-95. PubMed ID: 18440651 [TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
4. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646 [TBL] [Abstract][Full Text] [Related]
5. Differential immunostimulating effect of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and interferon gamma (IFNgamma) after severe trauma. Lendemans S; Kreuzfelder E; Waydhas C; Schade FU; Flohé S Inflamm Res; 2007 Jan; 56(1):38-44. PubMed ID: 17334669 [TBL] [Abstract][Full Text] [Related]
6. Granulocyte macrophage colony-stimulating factor expression in human herpetic stromal keratitis: implications for the role of neutrophils in HSK. Duan R; Remeijer L; van Dun JM; Osterhaus AD; Verjans GM Invest Ophthalmol Vis Sci; 2007 Jan; 48(1):277-84. PubMed ID: 17197544 [TBL] [Abstract][Full Text] [Related]
7. Maternal plasma cytokines in early- and mid-gestation of normal human pregnancy and their association with maternal factors. Curry AE; Vogel I; Skogstrand K; Drews C; Schendel DE; Flanders WD; Hougaard DM; Thorsen P J Reprod Immunol; 2008 Apr; 77(2):152-60. PubMed ID: 17692390 [TBL] [Abstract][Full Text] [Related]
8. [Cutaneous side effects of clinically relevant cytokine therapies]. Trefzer U; Hofmann M; Sterry W Dtsch Med Wochenschr; 2003 Aug; 128(34-35):1782-7. PubMed ID: 12934174 [No Abstract] [Full Text] [Related]
9. Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and other immunomodulatory therapies for the treatment of infectious diseases in solid organ transplant recipients. Page AV; Liles WC Curr Opin Organ Transplant; 2008 Dec; 13(6):575-80. PubMed ID: 19060545 [TBL] [Abstract][Full Text] [Related]
10. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Sakagami M Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1030-60. PubMed ID: 17010473 [TBL] [Abstract][Full Text] [Related]
11. [Response to inhaled granulocyte-macrophage colony-stimulating factor in a patient with alveolar proteinosis]. Rodríguez Portal JA; Rodríguez Becerra E; Sánchez Garrido A Arch Bronconeumol; 2009 Mar; 45(3):150-2. PubMed ID: 19286115 [TBL] [Abstract][Full Text] [Related]
12. Preclinical models for pulmonary drug delivery. Fernandes CA; Vanbever R Expert Opin Drug Deliv; 2009 Nov; 6(11):1231-45. PubMed ID: 19852680 [TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of inhaled insulin. Mastrandrea LD; Quattrin T Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1061-75. PubMed ID: 17070613 [TBL] [Abstract][Full Text] [Related]
14. Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology. Emami J; Hamishehkar H; Najafabadi AR; Gilani K; Minaiyan M; Mahdavi H; Mirzadeh H; Fakhari A; Nokhodchi A J Microencapsul; 2009 Feb; 26(1):1-8. PubMed ID: 18465287 [TBL] [Abstract][Full Text] [Related]
15. Nanoparticles for drug delivery to the lungs. Sung JC; Pulliam BL; Edwards DA Trends Biotechnol; 2007 Dec; 25(12):563-70. PubMed ID: 17997181 [TBL] [Abstract][Full Text] [Related]
16. Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors. Newton R; Holden NS; Catley MC; Oyelusi W; Leigh R; Proud D; Barnes PJ J Pharmacol Exp Ther; 2007 May; 321(2):734-42. PubMed ID: 17322026 [TBL] [Abstract][Full Text] [Related]